In early January 2026, Novo Nordisk rolled out the first FDA-approved oral semaglutide tablet for chronic weight management, branded as Wegovy. This launch follows positive phase III results showing an average weight reduction of 13.5% over 68 weeks in treated patients versus 2.3% for placebo. Retail cash-pay pricing has been publicly noted in industry sources to reside in the mid-hundreds of dollars per month, though insurance coverage details and patient out-of-pocket costs will vary by plan and dosing regimen. The arrival of an oral alternative transforms access for patients reluctant to adopt weekly injections and creates a novel commercial frontier for the company in the rapidly growing GLP-1 segment.

Novo Nordisk’s decision to extend its GLP-1 franchise into an oral format leverages its existing semaglutide intellectual property and manufacturing scale. The company reported that more than 3,500 participants were randomized in the pivotal oral semaglutide trial, making it one of the largest obesity drug studies to date. Analyst models project that the oral tablet could capture up to 20% of new weight-loss prescriptions in the U.S. by year end, potentially contributing an incremental $1.5 billion in annual revenue within two years. The shift also underscores Novo Nordisk’s strategy to foster patient adherence through convenience, a differentiator from injectable-only portfolios.

Following the U.S. debut of its oral Wegovy tablet, Novo Nordisk shares advanced by double digits in the first trading sessions of January, reflecting heightened investor confidence in the company’s first-mover advantage. Market research firms anticipate the global GLP-1 weight-loss market to exceed $75 billion by 2028, with oral formulations accounting for roughly one-third of that figure. Beyond U.S. expansion, Novo Nordisk is conducting additional trials to evaluate oral semaglutide in combination with other metabolic therapies, reinforcing a multi-pronged pipeline approach that supports long-term revenue growth and margin enhancement.